UNITED STATES
SECURITIES AND EXCHANGECOMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16OR 15d-16
UNDER THE SECURITIESEXCHANGE ACT OF 1934
For the month of May 2023
Commission File Number: 001-39461
NANO-X IMAGING LTD
Communications Center
Neve Ilan, Israel 9085000
(Address of principalexecutive office)
Indicate by check mark whether the registrant files or will file annualreports
under cover of Form 20-F or Form 40-F.
Form 20-F
Form40-F
Indicate by check mark if the registrant is submitting the Form 6-Kin paper as
permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) onlypermits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-Kin paper as
permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permitsthe submission in paper of a
Form 6-K if submitted to furnish a report or other document that the
registrant foreign private issuer mustfurnish and make public under the laws
of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (theregistrant's "home country"), or under the rules of the
home country exchange on which the registrant's securitiesare traded, as long
as the report or other document is not a press release, is not required to be
and has not been distributed to theregistrant's security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or otherCommission filing on EDGAR.
On May 14, 2023, NANO-X IMAGING LTD (the "Company")issued a press release, a
copy of which is attached hereto as Exhibit 99.1, and incorporated herein by
reference.
The information contained in this report ishereby incorporated by reference
into the Registration Statement on
FormS-8
, File No. 333-248322.
1
EXHIBIT INDEX
Exhibit No. Exhibit
99.1 Press release, dated May 1, 2023
2
SIGNATURES
Pursuant to the requirements of the SecuritiesExchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NANO-X IMAGING LTD
By: /s/ Ran Daniel
Name: Ran Daniel
Title: Chief Financial Officer
3
Exhibit 99.1
Nanox Files 2022 Annual Report on Form 20-F
NEVE ILAN, Israel--(BUSINESS WIRE)-May1, 2023-- NANO-X IMAGING LTD ("Nanox" or
the "Company," Nasdaq: NNOX), an innovative medical imagingtechnology company,
today announced that it has filed its annual report on Form 20-F for the
fiscal year ended December 31, 2022with the U.S. Securities and Exchange
Commission ("SEC") on May 1, 2023. The annual report on Form 20-F, which
containsthe Company's audited consolidated financial statements, can be
accessed on the SEC's website at www.sec.gov and on theCompany's website at
www.nanox.vision under "Financials" in the Investors section.
The Company will provide a hard copy of its annualreport containing its
audited consolidated financial statements, free of charge, to its shareholders
upon request. Requests should bedirected to Investor Relations, at
IR@nanox.vision.
About Nanox
We, NANO-X IMAGING LTD or Nanox -(Nasdaq: NNOX) are focused on applyingour
proprietary medical imaging technology and solutions to make diagnostic
medicine more accessible and affordable across the globe.
Nanox's vision is to increase access, reduce costs and enhancethe efficiency
of routine medical imaging technology and processes, in order to improve early
detection and treatment, which Nanox believesis key to helping people achieve
better health outcomes, and, ultimately, to save lives.
The Nanox ecosystem includes Nanox.ARC - a multi-source Digital Tomosynthesissys
tem that is cost-effective, and user-friendly; an AI-based suite of algorithms
that augment the readings of routine CT imaging to highlightearly signs often
related to chronic disease, (Nanox.AI); a cloud-based infrastructure
(Nanox.CLOUD); and a proprietary decentralizedmarketplace, through Nanox's
subsidiary, USARAD Holdings Inc., that provides remote access to radiology and
cardiology experts;and a comprehensive teleradiology services platform
(Nanox.MARKETPLACE).
Together, Nanox' products and services create a worldwide, innovative,and
comprehensive solution that connects medical imaging solutions, from scan to
diagnosis. For more information, please visit www.nanox.vision.
Forward-Looking Statements
This press release may contain forward-looking statements that aresubject to
risks and uncertainties. All statements that are not historical facts
contained in this press release are forward-looking statements.Such statements
include, but are not limited to, any statements relating to the initiation,
timing, progress and results of the Company'sresearch and development,
manufacturing, and commercialization activities with respect to its X-ray
source technology and the Nanox.ARC,the ability to realize the expected
benefits of its recent acquisitions and the projected business prospects of
the Company and the acquiredcompanies. In some cases, you can identify
forward-looking statements by terminology such as "can," "might,"
"believe,""may," "estimate," "continue," "anticipate," "intend," "should,""plan,
" "should," "could," "expect," "predict," "potential," orthe negative of these
terms or other similar expressions. Forward-looking statements are based on
information the Company has when thosestatements are made or management's good
faith belief as of that time with respect to future events and are subject to
risks anduncertainties that could cause actual performance or results to
differ materially from those expressed in or suggested by the forward-lookingsta
tements. Factors that could cause actual results to differ materially from
those currently anticipated include: risks related to (i)Nanox's ability to
continue to develop of the Nanox imaging system; (ii) Nanox's ability to
successfully demonstrate the feasibilityof its technology for commercial
applications; (iii) Nanox's expectations regarding the necessity of, timing of
filing for, andreceipt and maintenance of, regulatory clearances or approvals
regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatoryagencies
worldwide and its ongoing compliance with applicable quality standards and
regulatory requirements; (iv) Nanox's abilityto realize the anticipated
benefits of acquisitions, which may be affected by, among other things,
competition, brand recognition, theability of the acquired companies to grow
and manage growth profitably and retain their key employees; (v) Nanox's
ability to enterinto and maintain commercially reasonable arrangements with
third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi)the
market acceptance of the Nanox imaging system and the proposed pay-per-scan
business model; (vii) Nanox's expectations regardingcollaborations with
third-parties and their potential benefits; and (viii) Nanox's ability to
conduct business globally; (ix) changesin global, political, economic,
business, competitive, market and regulatory forces; and (x) risks related to
business interruptions resultingfrom the COVID-19 pandemic or similar public
health crises, among other things.
For a discussion of other risks and uncertainties, and other importantfactors,
any of which could cause Nanox's actual results to differ from those contained
in the Forward-Looking Statements, see thesection titled "Risk Factors" in
Nanox's Annual Report on Form 20-F for the year ended December 31, 2022 , and
subsequentfilings with the U.S. Securities and Exchange Commission. The reader
should not place undue reliance on any forward-looking statementsincluded in
this press release.
Except as required by law, Nanox undertakesno obligation to update publicly
any forward-looking statements after the date of this press release to conform
these statements to actualresults or to changes in the Company's expectations.
Contacts
Media Contact:
Rachael Roselli
ICR Westwicke
NanoxPR@icrinc.com
InvestorContact:
Mike Cavanaugh
ICR Westwicke
mike.cavanaugh@westwicke.com